{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T01:02:59Z","timestamp":1769130179706,"version":"3.49.0"},"reference-count":62,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/mjt.0b013e31804c7238","type":"journal-article","created":{"date-parts":[[2008,12,17]],"date-time":"2008-12-17T08:14:39Z","timestamp":1229501679000},"page":"e29-e40","source":"Crossref","is-referenced-by-count":19,"title":["Antiplatelet Intervention in Acute Coronary Syndrome"],"prefix":"10.1097","volume":"16","author":[{"given":"Rohit R","family":"Arora","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fasi","family":"Rai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-16-20210202","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0735-1097(02)02336-7","article-title":"ACC\/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina).","volume":"40","author":"Braunwald","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R3-16-20210202","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1001\/jama.293.23.2908","article-title":"Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials.","volume":"293","author":"Mehta","year":"2005","journal-title":"JAMA"},{"key":"R4-16-20210202","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(05)67222-4","article-title":"5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial.","volume":"366","author":"Fox","year":"2005","journal-title":"Lancet"},{"key":"R5-16-20210202","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.ehj.2004.07.032","article-title":"Do men benefit more than women from an interventional strategy in patients with unstable angina or non-ST-elevation myocardial infarction? The impact of gender in the RITA 3 trial.","volume":"25","author":"Clayton","year":"2004","journal-title":"Eur Heart J"},{"key":"R6-16-20210202","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0735-1097(01)01308-0","article-title":"Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators.","volume":"38","author":"Lagerqvist","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R7-16-20210202","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMe020049","article-title":"Decision making with cardiac troponin tests.","volume":"346","author":"Antman","year":"2002","journal-title":"N Eng J Med"},{"key":"R8-16-20210202","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/archinte.165.16.1870","article-title":"Relationship between risk stratification by cardiac troponin level and adherence to guidelines for non-ST-segment elevation acute coronary syndromes.","volume":"165","author":"Roe","year":"2005","journal-title":"Arch Intern Med"},{"key":"R9-16-20210202","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non-ST elevation MI: A method for prognostication and therapeutic decision making.","volume":"284","author":"Antman","year":"2000","journal-title":"JAMA"},{"key":"R10-16-20210202","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.CIR.0000015464.18023.0A","article-title":"Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.","volume":"105","author":"Sabatine","year":"2002","journal-title":"Circulation"},{"key":"R11-16-20210202","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jacc.2005.06.051","article-title":"The year in non-ST-segment elevation acute coronary syndromes.","volume":"46","author":"Giugliano","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R12-16-20210202","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1161\/01.ATV.0000166521.90532.44","article-title":"New links between inflammation and thrombosis.","volume":"25","author":"Wagner","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R13-16-20210202","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nm0405-375","article-title":"The shear stress of keeping arteries clear.","volume":"11","author":"Harrison","year":"2005","journal-title":"Nat Med"},{"key":"R14-16-20210202","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1161\/CIRCULATIONAHA.104.494468","article-title":"Molecular regulation of platelet-dependent thrombosis.","volume":"112","author":"Freedman","year":"2005","journal-title":"Circulation"},{"key":"R15-16-20210202","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1161\/01.ATV.0000184765.59207.f3","article-title":"CD40 ligand influences platelet release of reactive oxygen intermediates.","volume":"25","author":"Chakrabarti","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R16-16-20210202","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.CIR.0000028962.04520.01","article-title":"Platelet-derived CD40L: the switch-hitting player of cardiovascular disease.","volume":"106","author":"Andre","year":"2002","journal-title":"Circulation"},{"key":"R17-16-20210202","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.2165\/00003495-200565140-00007","article-title":"Eptifibatide: a review of its use in patients with acute coronary syndromes and\/or undergoing percutaneous coronary intervention.","volume":"65","author":"Curran","year":"2005","journal-title":"Drugs"},{"issue":"Suppl 4","key":"R18-16-20210202","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.ahj.2003.09.001","article-title":"Glycoprotein IIb\/IIIa inhibitors in patients with unstable angina\/non-ST-segment elevation myocardial infarction: appropriate interpretation of the guidelines.","volume":"146","author":"Antman","year":"2003","journal-title":"Am Heart J"},{"key":"R19-16-20210202","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1538-7836.2005.01124.x","article-title":"GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention.","volume":"3","author":"Furman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"R20-16-20210202","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"R21-16-20210202","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1197\/j.aem.2004.11.029","article-title":"Early glycoprotein IIb\/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns.","volume":"12","author":"Hoekstra","year":"2005","journal-title":"Academ Emerg Med"},{"key":"R23-16-20210202","first-page":"1488","article-title":"Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators.","volume":"338","year":"1998","journal-title":"N Eng J Med"},{"key":"R24-16-20210202","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.amjcard.2004.05.065","article-title":"Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).","volume":"94","author":"Morrow","year":"2004","journal-title":"Am J Cardiol"},{"key":"R25-16-20210202","first-page":"436","article-title":"The PURSUIT Trial Investigators. Platelet Glycoprotein IIb\/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.","volume":"339","year":"1998","journal-title":"N Eng J Med"},{"key":"R26-16-20210202","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1161\/01.CIR.101.7.751","article-title":"Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators.","volume":"101","author":"Kleiman","year":"2000","journal-title":"Circulation"},{"key":"R27-16-20210202","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1161\/01.CIR.102.10.1093","article-title":"Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb\/IIIa inhibition. Insights from the platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.","volume":"102","author":"Lincoff","year":"2000","journal-title":"Circulation"},{"key":"R28-16-20210202","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.284.12.1549","article-title":"Current role of platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes.","volume":"284","author":"Bhatt","year":"2000","journal-title":"JAMA"},{"key":"R29-16-20210202","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban.","volume":"344","author":"Cannon","year":"2001","journal-title":"N Eng J Med"},{"key":"R30-16-20210202","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1161\/01.CIR.0000112604.74713.35","article-title":"Implications of upstream glycoprotein IIb\/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina\/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 trial.","volume":"109","author":"Sabatine","year":"2004","journal-title":"Circulation"},{"key":"R31-16-20210202","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.amjcard.2004.04.066","article-title":"TIMI Study Group. Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy).","volume":"94","author":"Gibson","year":"2004","journal-title":"Am J Cardiol"},{"key":"R32-16-20210202","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/S0140-6736(00)03400-0","article-title":"Enhanced Suppression of the Platelet IIb\/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.","volume":"356","year":"2000","journal-title":"Lancet"},{"key":"R33-16-20210202","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00129784-200404010-00004","article-title":"Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.","volume":"4","author":"Granada","year":"2004","journal-title":"Am J Cardiovasc Drugs"},{"key":"R34-16-20210202","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0735-1097(00)00554-4","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade in coronary artery disease.","volume":"35","author":"Lincoff","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R35-16-20210202","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1161\/CIRCULATIONAHA.105.582346","article-title":"CRUSADE Investigators. Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC\/AHA guidelines) Registry.","volume":"112","author":"Ryan","year":"2005","journal-title":"Circulation"},{"key":"R36-16-20210202","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ehj.2003.10.027","article-title":"Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes.","volume":"25","author":"Roffi","year":"2004","journal-title":"Eur Heart J"},{"key":"R37-16-20210202","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.2337\/diacare.26.7.2181","article-title":"The platelet in diabetes: focus on prevention of ischemic events.","volume":"26","author":"Colwell","year":"2003","journal-title":"Diabetes Care"},{"key":"R38-16-20210202","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1161\/01.CIR.102.20.2466","article-title":"Glycoprotein IIb\/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina\/non-ST-elevation myocardial infarction: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study.","volume":"102","author":"Theroux","year":"2000","journal-title":"Circulation"},{"key":"R39-16-20210202","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/01.CIR.0000055653.52489.E9","article-title":"Important triad in cardiovascular medicine: diabetes, coronary intervention, and platelet glycoprotein IIb\/IIIa receptor blockade.","volume":"107","author":"Lincoff","year":"2003","journal-title":"Circulation"},{"key":"R40-16-20210202","first-page":"U808","article-title":"\"An early invasive strategy in women who present with high-risk non-ST-segment elevation acute coronary syndromes is associated with more aggressive pharmacotherapy and better in-hospital outcomes: Results from the CRUSADE improvement initiative.","volume":"112","author":"Boden","year":"2005","journal-title":"Circulation"},{"key":"R41-16-20210202","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1001\/jama.292.17.2096","article-title":"CRUSADE Investigators. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative.","volume":"292","author":"Bhatt","year":"2004","journal-title":"JAMA"},{"key":"R42-16-20210202","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1001\/jama.294.24.3108","article-title":"CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.","volume":"294","author":"Alexander","year":"2005","journal-title":"JAMA"},{"key":"R43-16-20210202","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s11886-003-0061-9","article-title":"McCullough. Acute Coronary Syndromes in Patients with Renal Failure.","volume":"5","author":"Peter","year":"2003","journal-title":"Current Cardiology Reports"},{"key":"R44-16-20210202","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/01.CIR.0000050144.67910.13","article-title":"Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb\/IIIa inhibitor eptifibatide.","volume":"107","author":"Goodman","year":"2003","journal-title":"Circulation"},{"key":"R45-16-20210202","first-page":"45","article-title":"SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.","volume":"292","author":"Ferguson","year":"2004","journal-title":"JAMA"},{"key":"R46-16-20210202","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"R47-16-20210202","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.jacc.2004.08.060","article-title":"ISAR-REACT Study Investigators. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization.","volume":"44","author":"Kandzari","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R48-16-20210202","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.105.559088","article-title":"Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial.","volume":"112","author":"Von Beckerath","year":"2005","journal-title":"Circulation"},{"key":"R49-16-20210202","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1161\/01.CIR.0000148956.93631.4D","article-title":"Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.","volume":"110","author":"Mehilli","year":"2004","journal-title":"Circulation"},{"key":"R50-16-20210202","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1161\/01.CIR.0000157138.02645.11","article-title":"Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.","volume":"111","author":"Gurbel","year":"2005","journal-title":"Circulation"},{"key":"R51-16-20210202","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.jacc.2005.01.030","article-title":"The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting.","volume":"45","author":"Gurbel","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R52-16-20210202","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"R53-16-20210202","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jama.289.7.853","article-title":"REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb\/IIIa blockade compared with heparin and planned glycoprotein IIb\/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.","volume":"289","author":"Lincoff","year":"2003","journal-title":"JAMA"},{"key":"R54-16-20210202","first-page":"588","article-title":"American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction).","volume":"110","author":"Antman","year":"2004","journal-title":"Circulation"},{"key":"R55-16-20210202","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0140-6736(03)12113-7","article-title":"Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.","volume":"361","author":"Keeley","year":"2003","journal-title":"Lancet"},{"key":"R56-16-20210202","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1161\/01.CIR.0000128736.57259.48","article-title":"Pharmacoinvasive Therapy The Future of Treatment for ST-Elevation Myocardial Infarction.","volume":"109","author":"Antman","year":"2004","journal-title":"Circulation"},{"key":"R57-16-20210202","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation"},{"key":"R58-16-20210202","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0002-9149(03)00891-9","article-title":"Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?","volume":"92","author":"Nallamothu","year":"2003","journal-title":"Am J Cardiol"},{"issue":"Suppl","key":"R59-16-20210202","doi-asserted-by":"crossref","first-page":"I10","DOI":"10.1093\/eurheartj\/sui062","article-title":"The use of GP IIb\/IIIa inhibitors into new perspectives: pre-catheterization laboratory administration.","volume":"7","author":"Beygui","year":"2005","journal-title":"Eur Heart J Suppl"},{"key":"R60-16-20210202","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/eurheartj\/ehi293","article-title":"Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial.","volume":"26","author":"Zeymer","year":"2005","journal-title":"Eur Heart J"},{"key":"R61-16-20210202","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/01.CIR.98.8.734","article-title":"Randomized, placebo-controlled trial of platelet glycoprotein IIb\/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.","volume":"98","author":"Brener","year":"1998","journal-title":"Circulation"},{"key":"R62-16-20210202","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0735-1097(99)00635-X","article-title":"Effect of glycoprotein IIb\/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction.","volume":"35","author":"Neumann","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R63-16-20210202","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"ADMIRAL Investigators. Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-Term Follow-up. Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction.","volume":"344","author":"Montalescot","year":"2001","journal-title":"N Eng J Med"},{"key":"R64-16-20210202","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jacc.2003.07.017","article-title":"A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction.","volume":"42","author":"Antoniucci","year":"2003","journal-title":"J Am Coll Cardiol"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e31804c7238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:33:59Z","timestamp":1620963239000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-200909000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e31804c7238","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}